Alps Advisors Inc Cogent Biosciences, Inc. Transaction History

Alps Advisors Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$8.24 - $11.48 $106,007 - $147,690	12,865 Added 17.25%	87,463 $944,000
Q2 2024 Aug 13, 2024	BUY	$6.01 - $9.04 $448,333 - $674,365	74,598 New	74,598 $628,000
Q1 2023 May 10, 2023	SELL	$10.04 - $15.5 $13,403 - $20,692	-1,335 Reduced 2.82%	46,045 $496,000
Q4 2022 Feb 14, 2023	BUY	$10.65 - $14.84 $122,251 - $170,348	11,479 Added 31.97%	47,380 $547,000
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $81,880 - $148,152	8,720 Added 32.08%	35,901 $536,000
Q2 2022 Aug 11, 2022	SELL	$3.92 - $9.73 $54,013 - $134,069	-13,779 Reduced 33.64%	27,181 $245,000
Q1 2022 May 16, 2022	SELL	$5.31 - $8.7 $27,378 - $44,857	-5,156 Reduced 11.18%	40,960 $307,000
Q4 2021 Feb 09, 2022	BUY	$7.51 - $10.81 $346,331 - $498,513	46,116 New	46,116 $396,000

190

104M

157K

439K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $526M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.